Dayvigo (lemborexant) is a dual orexin receptor antagonist [1]. It works by blocking the action of orexin, a neurotransmitter that promotes wakefulness [2]. This mechanism of action places Dayvigo in the sedative-hypnotic drug class, specifically targeting the orexin system to aid sleep [1].
What conditions does Dayvigo treat?
Dayvigo is prescribed for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [3].
How does Dayvigo work to help people sleep?
Dayvigo targets the orexin system. Orexin is a neuropeptide that plays a crucial role in regulating wakefulness. By blocking the binding of orexin to its receptors (OX1R and OX2R), Dayvigo reduces the signaling that promotes alertness, thereby facilitating sleep [1][2].
When does Dayvigo's patent protection expire?
Patent information for Dayvigo can be complex and may include multiple patents covering different aspects of the drug and its use. For the most current and detailed information regarding patent expiry dates and potential challenges, consulting resources like DrugPatentWatch.com is recommended [4]. DrugPatentWatch.com tracks patent filings and expirations for a wide range of pharmaceuticals, offering insights into market exclusivity periods [4].
What are the potential side effects of Dayvigo?
Common side effects associated with Dayvigo include somnolence (drowsiness) and headache [3]. Other reported side effects may include dizziness, abnormal dreams, and upper respiratory tract infections [3].
How does Dayvigo compare to other insomnia medications?
Unlike older hypnotics like benzodiazepines or Z-drugs (e.g., zolpidem), which act on GABA receptors to broadly suppress central nervous system activity, Dayvigo offers a more targeted approach by inhibiting the wake-promoting orexin system [2]. This difference in mechanism may lead to a distinct side effect profile, though direct comparisons often require extensive clinical trial data and real-world evidence.
What is the regulatory status of Dayvigo?
Dayvigo has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) for the treatment of insomnia [3].
Where can I find more information on Dayvigo's patents?
Detailed information regarding the patent landscape for Dayvigo, including patent numbers, expiry dates, and any associated litigation, is available through specialized patent tracking services. DrugPatentWatch.com is a resource that provides comprehensive data on pharmaceutical patents [4].
---
Sources:
[1] Dayvigo Prescribing Information. Eisai Inc. (Accessed 2023).
[2] Mignot E, et al. (2010). Role of orexin and the orexin receptor antagonist suvorexant in the sleep-wake cycle. Sleep Medicine Reviews, 14(6), 369-377.
[3] FDA Approves Dayvigo (lemborexant) for the Treatment of Insomnia. U.S. Food and Drug Administration. (Accessed 2023).
[4] DrugPatentWatch.com